Moleculin Biotech (MBRX) Assets Average (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Assets Average of $21.2 million for Q4 2025, up 5.36% year-over-year from $20.2 million in Q4 2024, and up 1.27% quarter-over-quarter from $21.0 million in Q3 2025.
Moleculin Biotech (MBRX) Assets Average (2016 - 2026) Analysis & Trends
Moleculin Biotech's Assets Average history runs 10 years deep, the most recent figure standing at $21.2 million for Q4 2025.
- In Q4 2025, Assets Average rose 5.36% year-over-year to $21.2 million; the TTM figure through Dec 2025 stood at $21.2 million (up 5.36% YoY), while the FY2025 annual figure was $19.5 million, down 29.18% from the prior year.
- Assets Average for Q4 2025 stood at $21.2 million, up from $21.0 million in the prior quarter.
- The five-year high for Assets Average was $96.7 million in Q2 2021, with the low at $19.0 million in Q1 2025.
- The 5-year median for Assets Average is $46.2 million (2023), against an average of $50.1 million.
- The sharpest annual moves came in 2021 and 2024: Assets Average surged 240.04% in 2021, then tumbled 48.14% in 2024.
- Moleculin Biotech's Assets Average stood at $86.4 million in 2021, then slipped by 28.94% to $61.4 million in 2022, then sank by 36.69% to $38.9 million in 2023, then plunged by 48.14% to $20.2 million in 2024, then gained by 5.36% to $21.2 million in 2025.
- Business Quant data shows MBRX's Assets Average at $21.2 million in Q4 2025, $21.0 million in Q3 2025, and $21.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | 21.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.61 Mn |
| Dec 31, 2025 | 21.24 Mn |
| Sep 30, 2025 | 20.97 Mn |
| Jun 30, 2025 | 21.30 Mn |
| Mar 31, 2025 | 18.97 Mn |
| Dec 31, 2024 | 20.16 Mn |
| Sep 30, 2024 | 24.48 Mn |
| Jun 30, 2024 | 28.21 Mn |
| Mar 31, 2024 | 34.53 Mn |
| Dec 31, 2023 | 38.87 Mn |
| Sep 30, 2023 | 43.32 Mn |
| Jun 30, 2023 | 49.09 Mn |
| Mar 31, 2023 | 54.24 Mn |
| Dec 31, 2022 | 61.40 Mn |
| Sep 30, 2022 | 69.31 Mn |
| Jun 30, 2022 | 76.03 Mn |
| Mar 31, 2022 | 81.45 Mn |
| Dec 31, 2021 | 86.40 Mn |
| Sep 30, 2021 | 91.12 Mn |
| Jun 30, 2021 | 96.66 Mn |